Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00223977 · ClinicalTrials.gov registry record · Phase 2
2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.
A Phase 2 study of Iron Deficiency Anemia, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
- 20
- Study locations
NCT00223977 is a Phase 2 study of Iron Deficiency Anemia that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 146 participants, below the 188-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT00223977, a Phase 2 study of Iron Deficiency Anemia, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 3 clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive one of two levels of Ferrlecit or oral iron in a 1:1:1 ratio.
Conditions Studied
Interventions
- DRUG Sodium Ferric Gluconate Complex
- DRUG Oral Iron
Study Locations (20)
California
- - Los Angeles
- - Torrance
Massachusetts
- - Springfield
- - Worcester
North Carolina
- - Chapel Hill
- - Winston-Salem
Alabama
- - Birmingham
Arizona
- - Mesa
Connecticut
- - New Haven
Illinois
- - Evanston
Louisiana
- - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2003-12 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00223977
The ClinicalTrials.gov registry entry for NCT00223977 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 188-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (22% lower). The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Iron Deficiency Anemia appearing as the primary indexed condition, and to 2 interventions - of which Sodium Ferric Gluconate Complex is the first listed.
NCT00223977 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00223977 about?
NCT00223977 is a clinical study titled "2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.". This is a phase 3 clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive one of two levels of Ferrlecit or oral iron in a 1:1:1 ratio.
What is the current status of trial NCT00223977?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2003-12. Estimated completion is 2008-02.
What conditions does trial NCT00223977 study?
This clinical trial studies the following conditions: Iron Deficiency Anemia.
What interventions are being tested in trial NCT00223977?
The interventions under investigation include: Sodium Ferric Gluconate Complex (DRUG), Oral Iron (DRUG).
Who is sponsoring clinical trial NCT00223977?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00223977 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Iron Deficiency Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants
RECRUITING · Phase 2
-
The Effect of H. Pylori Infection on Iron Metabolism
COMPLETED · Phase 2
-
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
RECRUITING · Phase 3
-
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
RECRUITING · Phase 3
-
Iron Deficiency Anemia (IDA) and the Brain
RECRUITING · Phase 4
-
Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.